Last quarter (Q ), GlobeStar Therapeutics's total revenue was $-163.76K, a decrease of -Infinity% from the same quarter last year. In Q, GlobeStar Therapeutics's net income was $-295.18K. See GlobeStar Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 23	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	$ -163.76K	-	-	-	$ 77.00	$ 425.00
Cost of Revenue	$ 84.46K	$ 42.23K	-	$ 2.41K	$ -37.68K	$ 154.00
Gross Profit	$ -205.99K	$ -42.23K	-	$ -2.41K	$ -37.60K	$ 271.00
Operating Expense	$ 1.86M	$ 1.86M	$ 1.27M	$ 9.09M	$ -266.07K	$ 316.14K
Operating Income	$ -1.86M	$ -1.86M	$ -1.27M	$ -9.09M	$ -303.67K	$ -315.87K
Net Non Operating Interest Income Expense	$ -88.82K	$ -91.60K	$ -222.75K	$ -707.40K	$ -238.06K	$ -360.36K
Other Income Expense	$ -6.72K	$ -6.72K	-	$ -225.00K	$ -187.00K	$ 1.16K
Pretax Income	$ -1.95M	$ -1.95M	$ -1.49M	$ -9.80M	$ -541.73K	$ -675.07K
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.08M	$ -1.95M	$ -1.49M	$ -9.80M	$ -541.73K	$ -2.28M
Basic EPS	-	-	-	-	-	$ -0.01
Diluted EPS	-	-	-	$ -0.02	-	$ -0.01
Basic Average Shares	-	-	-	$ 482.09M	$ 298.09M	$ 104.78M
Diluted Average Shares	-	-	-	$ 482.09M	-	$ 104.78M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.95M	$ 1.91M	$ 1.27M	$ 9.09M	$ -303.75K	$ 316.30K
Net Income From Continuing And Discontinued Operation	$ -1.95M	$ -1.95M	$ -1.49M	$ -9.80M	$ -541.73K	$ -675.07K
Normalized Income	$ -1.46M	$ -1.54M	-	-	-	$ -676.23K
Interest Expense	-	-	-	-	-	$ 360.36K
EBIT	$ -1.86M	$ -1.86M	$ -1.42M	$ -9.09M	$ -303.67K	$ -314.71K
EBITDA	$ -1.69M	$ -1.82M	$ -1.36M	$ -8.82M	$ -77.06K	$ -314.24K

Currency in USD

GlobeStar Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing